Showing results (141-150 of 164) with videos related to
Sort By:
Pageof 17
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|November 16, 2025
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancerLinrui Ma, Xiangyu Zhang, Shidong Xu, et al.Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.Cancer Cell|March 19, 2020
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 AxisHong Liu, Xinwei Kuang, Yongchang Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|August 2, 2025
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancerLiang Zeng, Fan Tong, Xingxiang Xu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature ReviewYang Xia, Kaiwen Wang, Jing Zhao, et al.Cancer Cell|June 18, 2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancerJun Liao, Wenxiu Yao, Yan Yu, et al.The New England Journal of Medicine|October 22, 2025
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLCWenfeng Fang, Lin Wu, Xiangjiao Meng, et al.The Journal of Experimental Medicine|January 29, 2024
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activationZhen Qin, Meiting Yue, Shijie Tang, et al.Nature Communications|December 15, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trialLiang Zeng, Zhaohui Ruan, Huan Yan, et al.Pageof 17